Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antisense oligonucleotide MDM2 - Aceragen

Next Previous
Drug Profile

Research programme: antisense oligonucleotide MDM2 - Aceragen

Alternative Names: GEM 240; HDMAS5; Research programme: anti-MDM2 antisense oligonucleotides

Latest Information Update: 20 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Idera Pharmaceuticals; Johns Hopkins University; University of Alabama
  • Developer Aceragen; Sanofi; University of Alabama
  • Class Antineoplastics; Nucleotides
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 17 Jan 2023 Idera Pharmaceuticals is now called Aceragen
  • 31 Mar 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 13 Sep 2005 Hybridon is now called Idera Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top